News
GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing ...
Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...
6d
MedPage Today on MSNSemaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
India stands on the brink of a weight-loss revolution as semaglutide, the key ingredient in blockbuster drugs like Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results